<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>International Seminars in Surgical Oncology - Most viewed articles</title>
		<link>http://www.issoonline.commostviewed/</link>
		<description>Most viewed articles in last 30 days from International Seminars in Surgical Oncology (ISSN 1477-7800) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/5/1/12"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/5/1/14"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/5/1/16"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/5/1/15"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/5/1/11"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/3/1/1"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/5/1/3"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/5/1/9"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/2/1/2"/>			    
            
				    <rdf:li rdf:resource="http://www.issoonline.com/content/3/1/13"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.issoonline.com/content/5/1/12">
            
            <title>Mirizzi Syndrome: an unexpected problem of cholelithiasis. Our experience with 27 cases</title>
			<description>PurposeMirizzi syndrome is a rare complication of long standing cholelithiasis. The purpose of this study is to retrospectively estimate the diagnostic and treatment methods applied in patients with Mirizzi syndrome.Materials and methodsOur experience with 27 cases with Mirizzi syndrome is presented. They were diagnosed either by imaging techniques, or during surgical operation. All of the patients were managed surgically.
Results:
8 patients were diagnosed preoperatively and the rest intraoperatively. Morbidity rate after surgery was 18,5%, and mortality rate was zero. The patients presented free of symptoms three months after surgery during the follow-up.
Conclusion:
Mirizzi syndrome is rarely diagnosed preoperatively and US proved inadequate for this purpose. Surgery is the only therapy and usually provides additionally definitive diagnosis.</description>
			<link>http://www.issoonline.com/content/5/1/12</link>		
			<dc:creator>Michael Safioleas, Michael Stamatakos, Panagiotis Safioleas, Anastasios Smyrnis, Constantinos Revenas and Constantinos Safioleas</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2008, 5:12</dc:source>
			<dc:subject>Number of accesses: 450</dc:subject>
			<dc:date>2008-05-21</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-5-12</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/5/1/14">
            
            <title>Metastatic Hurthle Cell Carcinoma of the thyroid presenting as a Breast Lump: A Case Report</title>
			<description>Background:
Hurthle cell carcinoma of the thyroid is a rare form of thyroid cancer. It may present as a low grade tumour or can present as a more aggressive metastatic carcinoma. Hurthle cell carcinoma has the highest incidence of metastasis among all differentiated thyroid cancers. Most commonly haematogenous spread to lungs, bones and brain, however spread to regional lymph nodes is not uncommon. The breast is a rare site for metastasis from extramammary sources. We present the first case of breast metastasis from Hurthle cell carcinoma of the thyroid.Case presentationWe report a 77 year old lady who had total thyroidectomy and bilateral neck dissection followed by radiotherapy for a high grade metastatic Hurthle cell carcinoma of the thyroid. Ten months later she presented to the breast clinic with left breast lump and a lump at the left axilla. Fine needle aspiration cytology of the lumps and histology after wide local excision of the breast lump confirmed metastatic Hurthle cell carcinoma.
Conclusion:
The presence of breast lumps in patients with history of extramammary cancer should raise the possibility of metastasis.</description>
			<link>http://www.issoonline.com/content/5/1/14</link>		
			<dc:creator>Yahya Al-Abed, Emma Gray, Konrad Wolfe, Gavin W Watters and Jonathan M Philpott</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2008, 5:14</dc:source>
			<dc:subject>Number of accesses: 417</dc:subject>
			<dc:date>2008-05-27</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-5-14</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/5/1/16">
            
            <title>Women with large breasts are at an increased risk of advanced breast cancer</title>
			<description>Background:
The risk of nodal metastasis is higher in women with bigger breast. It is not clear if this increase is due to the size of the breast (largely related to obesity) or is the result of larger tumour size at presentation (due to delayed diagnosis). It is hypothesised that women with large breasts are more likely to have node positive disease mainly attributable to their breast size.
Patients and Methods
One hundred and twenty consecutive patients who underwent mastectomy during the year 2004 and 2005 for primary breast cancers in a large Teaching Hospital were included in the study. Patientas variable and tumour variable were collected and analysed by SPSSA(R) computer programme. 	
Result
It was found that big breasted women (those patients with mastectomy weight greater than 800g) had a significantly greater tumour size than those with smaller breasts (p=0.019, Mann-Whitney test) but there was no significant difference in grade (Kendall's tau-b = 0.055, p=0.57) or lymph node positivity (Kendall's tau-b = 0.011, p=0.93) between the two groups. Although, the tumour size was significantly greater in those with lymph 
node metastases (p &lt;0.001) but mastectomy weight was not found to be significantly greater in those with lymph node metastases (p=0.11). For patients with similar tumour sizes mastectomy weight was not significantly greater in those patients with lymph node metastases (p=0.28). 
Conclusion:
It is concluded that increased incidence of lymph node positivity at presentation big-breasted women is because of larger size of the primary tumour and not due to the size of the breast alone.	</description>
			<link>http://www.issoonline.com/content/5/1/16</link>		
			<dc:creator>Chaminda Sellahewa, Peter Nightingale and Amtul R Carmichael</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2008, 5:16</dc:source>
			<dc:subject>Number of accesses: 413</dc:subject>
			<dc:date>2008-06-30</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-5-16</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/5/1/15">
            
            <title>Uterine leiomyomas with tubules</title>
			<description>.
We report two cases of uterine leiomyoma with tubules as a new pathological entity. Since these are biphasic neoplasms (composed by epithelial and mesenchimal elements), the differential diagnosis is between mixed mullerian tumours and uterine tumors resembling ovarian sex cord tumors (UTROSCTs). In the differential diagnosis, the mixed mullerian tumors are easily excluded because of their specific histological and immunohistochemical features. UTROSCTs are similar to the lesions we reported and the differential diagnosis requires positivity for immunohistochemical markers as inhibin, CD99, calretinin, Melan-A. Our conclusions are that to perform a diagnosis of UTROSCT at least two immunohistochemical marker have to be expressed. In the present case they did not, so we called the lesion leiomyoma with tubules.</description>
			<link>http://www.issoonline.com/content/5/1/15</link>		
			<dc:creator>Teresa Pusiol, Annamaria Parolari and Francesco Piscioli</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2008, 5:15</dc:source>
			<dc:subject>Number of accesses: 371</dc:subject>
			<dc:date>2008-06-09</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-5-15</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-09</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/5/1/11">
            
            <title>Exophytic growth of a neglected giant subcutaneous Leiomyosarcoma of the lower extremity. A case report</title>
			<description>Background:
Superficial leiomyosarcoma is an exceedingly uncommon malignant tumor which could be located either to cutaneous or subcutaneous tissues. Increased mass size and depth, advanced tumor staging and inadequate surgical excision are the main prognostic factors for poor result.Case presentationWe report a rare case of a 71-year-old man with an extensive exophytic lesion (12 &#215; 10 cm) in the anterior-medial side of the proximal right tibia. The lesion was painless and consistently neglected by the patient until a skin trauma caused ulceration of the affected area. Magnetic Resonance Imaging revealed a soft-tissue mass which was well defined from the surrounding bone and muscles. As initial biopsy in another hospital hadn't clarified the true nature of the lesion, new samples were taken and the diagnosis of leiomyosarcoma was established. Laboratory examination showed no distant metastasis and wide excision of the neoplasm was decided. After tumor resection, the remaining soft tissue and skin defect was covered with a gastrocnemius myocutaneous flap. The postoperative period was uneventful and wound healing was followed by local radiotherapy and systemic chemotherapy. At 3 years follow up, no recurrence or metastasis was identified and the patient was able to walk and stand without impairment of his ambulatory status.
Conclusion:
Proper surgical management of soft tissue leiomyosarcoma continues to remain the cornerstone of treatment efficacy and the most important prognostic factor for patients' survival. Reconstruction of the remaining soft tissue defect should be always performed at the same operative time when removal of giant size tumors leaves an uncovered cavity with an inadequate sleeve of muscular and skin tissues.</description>
			<link>http://www.issoonline.com/content/5/1/11</link>		
			<dc:creator>Marina Angeloni, Francesco Muratori, Nicola Magarelli, Byron E Chalidis, Riccardo Ricci, Barbara Rossi and Giulio Maccauro</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2008, 5:11</dc:source>
			<dc:subject>Number of accesses: 308</dc:subject>
			<dc:date>2008-05-21</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-5-11</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/3/1/1">
            
            <title>Breast papillomas: current management with a focus on a new diagnostic and therapeutic modality</title>
			<description>Breast papilloma is a term that describes an intraductal papillary configuration of the mammary epithelium on macroscopic or microscopic examination. It includes solitary intraductal papillomas, multiple papillomas, papillomatosis, and juvenile papillomatosis (JP).Recent advances in mammary ductoscopy (MD) have raised new possibilities in the diagnosis and treatment of breast papillomas. This technique represents an important diagnostic adjunct in patients with pathological nipple discharge (PND) by allowing direct visualisation and biopsy of intraductal lesions and guiding duct excision surgery.Treatment of breast papillomas often entails surgical duct excision for symptomatic relief and histopathological examination. Recently, more conservative approach has been adapted. MD-assisted microdochectomy should be considered the procedure of choice for a papilloma-related single duct discharge. Furthermore, there is increasing evidence that MD has the potential to reduce the number of duct excision procedures and minimise the extent of surgical resection. Imaging-guided vacuum-assisted core biopsy can be diagnostic and therapeutic for papillomas seen on mammography and/or ultrasound.Patients with multiple papillomas do have an increased risk of developing cancer and should be kept under annual review with regular mammography (preferably digital mammography) if treated conservatively. Magnetic resonance (MR) can be also used in surveillance in view of its high sensitivity. Because the risk is small, long term and affects both breasts, long-term follow-up is more appropriate than prophylactic mastectomy. Patients who prove to have solitary duct papilloma have insufficient increase in the risk of subsequent malignancy to justify routine follow-up.</description>
			<link>http://www.issoonline.com/content/3/1/1</link>		
			<dc:creator>W Al Sarakbi, D Worku, PF Escobar and K Mokbel</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2006, 3:1</dc:source>
			<dc:subject>Number of accesses: 297</dc:subject>
			<dc:date>2006-01-17</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-3-1</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2006-01-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/5/1/3">
            
            <title>A case of unilateral keloid after bilateral breast reduction</title>
			<description>Keloid scar is a manifestation of abnormal wound healing in predisposed individuals. Many treatment modalities have been tried with varying degrees of success. Radiotherapy is one such modality that is widely recognised. We present a case report and literature review based on a patient who developed unilateral keloid scarring following bilateral breast reduction surgery. Some 4 years previously, she had undergone breast conserving surgery followed by adjuvant radiotherapy for breast cancer. After her breast reduction surgery, she developed keloid scarring on the non-irradiated breast only. This case highlights a possible 'preventative' effect of radiotherapy in keloid formation.</description>
			<link>http://www.issoonline.com/content/5/1/3</link>		
			<dc:creator>Haresh Devalia, Lucy Mansfield, Neda Minakaran and Dibyesh Banerjee</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2008, 5:3</dc:source>
			<dc:subject>Number of accesses: 288</dc:subject>
			<dc:date>2008-02-24</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-5-3</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/5/1/9">
            
            <title>The role of Herceptin in early breast cancer</title>
			<description>Herceptin is widely regarded as the most important development in the treatment of breast cancer since Tamoxifen and the development of the multidisciplinary team (MDT). It is particularly exciting from an oncological polint of view as it represents success in the emerging field of specific targeted therapies to specific molecular abnormalities in tumour cells. This review will focus on the nature of the Her2 overexpression and the role of herceptin in the treatment of early breast cancer.</description>
			<link>http://www.issoonline.com/content/5/1/9</link>		
			<dc:creator>Ashok Subramanian and Kefah Mokbel</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2008, 5:9</dc:source>
			<dc:subject>Number of accesses: 270</dc:subject>
			<dc:date>2008-04-28</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-5-9</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/2/1/2">
            
            <title>Lessons learnt from the painful shoulder; a case series of malignant shoulder girdle tumours misdiagnosed as frozen shoulder</title>
			<description>Adhesive capsulitis or frozen shoulder is a common condition characterized by shoulder pain and stiffness. In patients in whom conservative measures have failed, more invasive interventions such as arthrographic or arthroscopic distension can be very effective in relieving symptoms and improving range of movement. However, absolute contraindications to these procedures include the presence of neoplasia around the shoulder girdle. We present five cases referred to our institution where the diagnosis of shoulder joint malignancy was delayed, following prolonged, ineffective treatment for frozen shoulder. These cases highlight the importance of careful review of the radiology and the need for reconsideration of the diagnosis in refractory "frozen shoulder".</description>
			<link>http://www.issoonline.com/content/2/1/2</link>		
			<dc:creator>Gerald MY Quan, Derek Carr, Steven Schlicht, Gerard Powell and Peter FM Choong</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2005, 2:2</dc:source>
			<dc:subject>Number of accesses: 268</dc:subject>
			<dc:date>2005-01-12</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-2-2</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>2</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2005-01-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.issoonline.com/content/3/1/13">
            
            <title>Transanal endoscopic micro-surgery (TEMS) for the management of large or sessile rectal adenomas: a review of the technique and indications</title>
			<description>In this review article the surgical technique of Transanal Endoscopic Microsurgery (TEMS) is examined. A number of techniques have been used to treat adenomas of the rectum. The treatment of large adenomas which occupy a large surface of the rectal lumen or adenomas which are flat and grow in a "carpet-like" fashion is particularly challenging. Major rectal surgery carries a risk of morbidity and mortality, particularly in elderly and unfit patients. Although local excision with transanal resection (TAR) and the Kraske sacral operation have been used in the past, during the last twenty years TEMS has become the method of choice for those lesions. TEMS is efficient and minimally invasive. The technique allows the patient to recover rapidly and the incidence of complications is much lower than that of major surgery. In case of recurrence the option of repeat TEMS or major surgery remain available. TEMS has been slow to gain popularity mainly for reasons of cost and steep learning curve but it is now an established procedure and a valuable therapeutic option which is particularly useful for elderly and unfit patients. Gastroenterologists should be aware of the nature and indications of TEMS in order to advise and refer selected patients with rectal adenomas accordingly.</description>
			<link>http://www.issoonline.com/content/3/1/13</link>		
			<dc:creator>Savvas Papagrigoriadis</dc:creator>
			<dc:source>International Seminars in Surgical Oncology 2006, 3:13</dc:source>
			<dc:subject>Number of accesses: 263</dc:subject>
			<dc:date>2006-05-04</dc:date>
			<dc:identifier>doi:10.1186/1477-7800-3-13</dc:identifier>
			
			
							
					<prism:publicationName>International Seminars in Surgical Oncology</prism:publicationName>
					
			
							
					<prism:issn>1477-7800</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2006-05-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
